Compositions and methods for treating chronic inflammation and inflammatory diseases
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
1. A pharmaceutical composition comprising:
a) a pharmaceutically-acceptable form of a propionic acid derived non-steroidal anti-inflammatory drug (NSAID) in a concentration of about 100 mg/mL to about 1,000 mg/mL;
b) less than about 20% by weight of the composition of a pharmaceutically-acceptable liquid polyethylene glycol (PEG) polymer; and
c) at least 50% by weight of the composition of pharmaceutically-acceptable glycerolipids comprising monoglycerides, diglycerides, and triglycerides;
wherein the pharmaceutical composition is formulated to have a melting point temperature of about 30° C. or higher.
2. The pharmaceutical composition according to claim 1 , wherein the concentration of the propionic acid derived NSAID is about 250 mg/mL to about 750 mg/mL.
3. The pharmaceutical composition according to claim 1 , wherein the concentration of the propionic acid derived NSAID is about 250 mg/mL to about 500 mg/mL.
4. The pharmaceutical composition according to claim 1 , wherein the propionic acid derived NSAID is a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
5. The pharmaceutical composition according to claim 1 , wherein the propionic acid derived NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen.
6. The pharmaceutical composition according to claim 1 , wherein the propionic acid derived NSAID is an ester thereof.
7. The pharmaceutical composition according to claim 1 , wherein the liquid PEG polymer is in an amount of less than about 15% by weight of the composition.
8. The pharmaceutical composition according to claim 7 , wherein the liquid PEG polymer is in an amount of about 8% to about 15% by weight of the composition.
9. The pharmaceutical composition according to claim 8 , wherein the liquid PEG polymer is in an amount of about 8% to about 12% by weight of the composition.
10. The pharmaceutical composition according to claim 7 , wherein the liquid PEG polymer is in an amount of about 4% to about 10% by weight of the composition.
11. The pharmaceutical composition according to claim 10 , wherein the liquid PEG polymer is in an amount of about 6% to about 10% by weight of the composition.
12. The pharmaceutical composition according to claim 1 , wherein the liquid PEG polymer is PEG 400.
13. The pharmaceutical composition according to claim 1 , wherein the amount of the pharmaceutically-acceptable glycerolipids is about 50% to about 95% by weight of the composition.
14. The pharmaceutical composition according to claim 1 , wherein the amount of the pharmaceutically-acceptable glycerolipids is at least 60% by weight of the composition.
15. The pharmaceutical composition according to claim 1 , wherein the amount of the triglycerides is at least 30% by weight of the composition.
16. The pharmaceutical composition according to claim 15 , wherein the amount of the triglycerides is at least 35% by weight of the composition.
17. The pharmaceutical composition according to claim 1 , wherein the amount of the monoglycerides is at least 10% by weight of the composition.
18. The pharmaceutical composition according to claim 17 , wherein the amount of the monoglycerides is at least 15% by weight of the composition.
19. The pharmaceutical composition according to claim 1 , wherein the melting point temperature is about 33° C. to about 35° C.
20. The pharmaceutical composition according to claim 1 , wherein the melting point temperature is about 30° C. to about 34° C.